Pipeline

Avanir is innovation.

By focusing on disorders of the central nervous system, we strive to meet the needs of patients with innovative solutions. Below is an overview of our pipeline, updated quarterly.

AVP-825

Acute Migraine in Adolescents
Phase 1(Planned)
Phase 2(Planned)
Phase 3(Planned)
Phase 4

Description/Summary

The objective of the study is to evaluate the safety and efficacy of AVP-825 compared to placebo in the acute treatment of migraine in adolescent patients, 12 through 17 years-of-age.

AVP-786

Agitation in Alzheimer's (US)
Phase 1(Planned)
Phase 2(Planned)
Phase 3(Planned)
Phase 4

Description/Summary

The objectives of the studies are to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of agitation in patients with dementia of the Alzheimer’s type.

Agitation in Alzheimer's (Global)
Phase 1(Planned)
Phase 2(Planned)
Phase 3(Planned)
Phase 4

Description/Summary

The objectives of the studies are to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of agitation in patients with dementia of the Alzheimer’s type.

Negative Symptoms of Schizophrenia
Phase 1(Planned)
Phase 2(Planned)
Phase 3(Planned)
Phase 4

Description/Summary

The objectives of this study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with schizophrenia who have predominantly negative symptoms.

Intermittent Explosive Disorder
Phase 1(Planned)
Phase 2(Planned)
Phase 3(Planned)
Phase 4

Description/Summary

The objectives of the study are to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment in patients with Intermittent explosive disorder (IED). 

Traumatic Brain Injury Behavioral Dysfunction
Phase 1(Planned)
Phase 2(Planned)
Phase 3(Planned)
Phase 4

Description/Summary

The objectives of the study are to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of neurobehavioral disinhibition such as aggression, agitation, and irritability in patients with traumatic brain injury.

Disclaimer

 

Block 1 - Job Block

Medical Director, Clinical Development

Aliso Viejo, CA

The Medical Director, Clinical Development is responsible for the design, planning and medical oversight of clinical studies for all phases of development …

Continue Reading

Director of Clinical Development
Joel Modayil
Neuroscience Area Manager, Long Term Care
Block 3 - Job Block

Corporate Controller

Aliso Viejo, CA

As a key leader in the Company’s finance organization, the Corporate Controller is responsible for managing the Company’s Accounting function …

Continue Reading

Corporate Controller
Tim Bareham
Field Sales Trainer-LTC
Block 4 - Job Block

Unlock the future of CNS treatment

Join our team of Innovators

Avanir employees are a diverse team of dedicated, accomplished professionals united by a common purpose: striving to make a change by developing innovative treatments for central nervous system (CNS) conditions.

View open opportunities at Avanir

Join our team of Innovators